Home › Premarket Biotech Digest: Gilead's Upcoming Earnings, Setback For AstraZeneca, Zafgen Tumbles 50%
 

Keywords :   


Premarket Biotech Digest: Gilead's Upcoming Earnings, Setback For AstraZeneca, Zafgen Tumbles 50%

2015-10-19 16:04:07| Biotech - Topix.net

The consensus forecast for Q3 revenue is at $7.81 billion, which is below the $8.24 billion reported in the previous quarter. The slight decline in revenue is due to a slowdown in the U.S. Hep C sales.

Tags: upcoming earnings digest biotech

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Graphics
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 6
More »